Previous 10 | Next 10 |
Regulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical Science PR Newswire SAN DIEGO , Sept. 30, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused...
Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire SAN DIEGO , Sept. 9, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and develo...
The following slide deck was published by Regulus Therapeutics Inc. in conjunction with this event. For further details see: Regulus Therapeutics (RGLS) Investor Presentation - Slideshow
Regulus Therapeutics Inc. (RGLS) Q2 2021 Earnings Conference Call August 10, 2021 5:00 PM ET Company Participants Cris Calsada – Chief Financial Officer Jay Hagan – President and Chief Executive Officer Denis Drygin – Chief Scientific Officer Conference Call Participants ...
Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent Updates Completed Preparations and Request for FDA Meeting to Obtain Feedback on Approach to Addressing Remaining Hold Requirements Completed Enrollment in Second Cohort of Trial; Topline Data Expe...
Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call --Company also Announces Participation in a Panel Discussion at the 2021 Wedbush PacGrow Healthcare Conference PR Newswire SAN DIEGO , Aug, 3, 2021 /PRNews...
Are These Popular Penny Stocks Worth Watching in August? Right now, the market on penny stocks is hot. This is marked by high volume and several days with overwhelming bullish sentiment. While not all penny stocks are worth buying, with the right research it can be easy to find the ...
Today, we take an in-depth look at Regulus Therapeutics. This small cap developmental firm is focused on microRNA therapeutics and has multiple 'shots on goal' in its pipeline. A full investment analysis follows in the paragraphs below. For further details see: The Read ...
Regulus Therapeutics (RGLS) presents additional data from the first cohort of patients in its Phase 1b clinical trial of RGLS4326 for the treatment of autosomal dominant polycystic kidney disease ((ADPKD)), as well as new preclinical data from relevant animal models of the disease.The Phase 1...
Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 Study demonstrates clinical proof of mechanism with statistically significant increases in polycystin levels following RGLS4326 treatment in th...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...